ERS Genomics
ERS Genomics Licenses CRISPR-Cas9 Patents to Crown Bioscience
ERS was founded to provide access to CRISPR-Cas9 patents held by Emmanuelle Charpentier, who shares the IP with Jennifer Doudna, UC, and the University of Vienna.
ERS Genomics Licenses CRISPR-Cas9 IP to Cosmo Bio
ERS was founded to provide access to CRISPR-Cas9 patents stemming from research conducted at the University of California and the University of Vienna.
In Brief This Week: 908 Devices, Natera, PerkinElmer, Hologic, Hamilton, BioFluidiX, More
News items for the week of Nov. 14, 2022
ERS Genomics Licenses CRISPR/Cas9 IP to Lepton Pharmaceuticals
Lepton, based in Israel, is developing a technology that engineers microRNAs to improve the efficiency and longevity of cells used in cell-based cancer immunotherapies.
ERS Genomics Licenses CRISPR Tech to Swiss Firm Cytosurge
ETH Zurich spinout Cytosurge develops single-cell research solutions and offers a CRISPR-based cell line engineering service.
Jul 27, 2021
ERS Genomics Licenses CRISPR IP to Japan SLC
Jun 7, 2021
ERS Genomics Licenses CRISPR IP to GenOway
Apr 19, 2021
ERS Genomics Licenses CRISPR Patents to Nuvisan
Mar 10, 2021